Drug Profile
Lyme disease vaccine - AstraZeneca/Sanofi-Aventis
Latest Information Update: 06 Apr 2022
Price :
$50
*
At a glance
- Originator Texas A&M University
- Developer MedImmune; Texas A&M University
- Class Bacterial vaccines; Lyme disease vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Lyme disease
Most Recent Events
- 19 Jun 2007 MedImmune has been acquired by AstraZeneca
- 04 Oct 2004 Discontinued - Preclinical for Lyme disease in USA (unspecified route)
- 31 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis